Rheumatology key messagesImmunization to biologic therapies is common in JIA patients and varies considerably across biologic agents.Anti-drug antibodies in JIA patients are frequently associated with treatment failure and hypersensitivity events.Strategies to predict, prevent, detect and manage immunogenicity of biologics could optimize outcomes in JIA.

Introduction
============

JIA is the most common rheumatic disease during childhood, with a prevalence of 16--150 per 100 000, affecting over 60 000 children in Europe alone \[[@kez030-B1], [@kez030-B2]\]. JIA is defined as arthritis of unknown aetiology that begins prior to the age of 16 years and persists for at least 6 weeks, while other causes of arthritis have been excluded \[[@kez030-B3]\]. JIA comprises a heterogeneous group of diseases divided into seven categories according to the distribution of arthritis, systemic manifestations and laboratory features \[[@kez030-B3], [@kez030-B4]\]. If left untreated, this disease can lead to severe short-term and long-term disability \[[@kez030-B4]\].

Biologic therapies have drastically improved treatment outcomes of JIA over the past two decades \[[@kez030-B5]\]. Nevertheless, up to 50% of JIA patients do not respond to initial biologic agents (primary failure), lose efficacy over time (secondary failure), or develop adverse events resulting in treatment discontinuation \[[@kez030-B6]\]. Recent studies of chronic inflammatory diseases in adult patients have investigated the ability of biologic agents to induce antibody formation, termed immunogenicity, in relation to treatment failure and adverse events. These studies demonstrated that the presence of anti-drug antibodies (ADAbs) was indeed associated with primary failure, secondary failure and hypersensitivity reactions \[[@kez030-B9], [@kez030-B10]\].

Two mechanisms have been suggested for how ADAbs are able to reduce treatment efficacy. First of all, neutralizing ADAbs (i.e. antibodies that bind to the target-binding region of a biologic agent) can directly prevent binding of biologic agents to their therapeutic target \[[@kez030-B11]\]. Secondly, both neutralizing and non-neutralizing ADAbs can result in the formation of immune complexes by binding to the drug, which increase drug clearance and result in lower effective drug concentrations \[[@kez030-B12], [@kez030-B13]\]. The pathogenic mechanisms of ADAbs involved in adverse events are not yet fully understood \[[@kez030-B14]\].

The presence of ADAbs may also affect clinical efficacy and safety of biologic therapies in JIA patients. However, knowledge on ADAbs in JIA remains scarce and guidelines on the detection and management of immunogenicity do not exist. Therefore, the main objective of this systematic review and meta-analysis was to summarize the prevalence of ADAbs in patients with JIA across different biologic agents. Furthermore, we investigated the clinical relevance of ADAbs regarding their effect on treatment efficacy, safety and the effect of immunosuppressive therapy on the formation of ADAbs.

Methods
=======

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analysis guidelines \[[@kez030-B15]\].

Eligibility criteria
--------------------

Briefly, the following criteria were used to select articles for inclusion in this review: patients with a diagnosis of JIA according to the ILAR classification criteria; treatment with any biologic or biosimilar agent; and ADAb measurements. We included randomized clinical trials, non-randomized clinical trials and observational studies (both prospective and retrospective) published in peer-reviewed journals. We excluded articles with multiple disease states when the prevalence of ADAbs could not be determined for patients with JIA only. Full eligibility criteria with rationale are provided in Supplementary [Table S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online.

Information sources
-------------------

A comprehensive search strategy was developed to identify relevant studies from published literature in PubMed (MEDLINE), Embase and Cochrane Library up to 16 July 2018. The majority of studies on efficacy, safety and pharmacokinetics report immunogenicity data without including key terms such as 'ADAbs' or 'immunogenicity' in their title or abstract. Therefore, the search strategy was only limited by synonyms for JIA and any biologic or biosimilar agent (search terms and search strategies are provided in [Supplementary Table S2](#sup1){ref-type="supplementary-material"} and [Supplementary Material](#sup1){ref-type="supplementary-material"}, section Full Search Strategy, available at *Rheumatology* online). In addition to the database search, reference lists of included articles were searched to identify additional relevant studies. Study protocols and trial registration databases (clinicaltrials.gov and clinicaltrialsregister.eu) were searched for additional information on included studies.

Study selection
---------------

Records were screened on title and abstract by one author (M.D.). Original research that addressed efficacy, safety or pharmacokinetics of biologic agents was independently reviewed in full-text by two authors (M.D. and J.S.) and publications that met all eligibility criteria were included in the review. Disagreements were resolved by discussion between the two authors. In case of identical study data across publications, only the most recent article was included.

Data collection
---------------

Authors extracted relevant data into tabulated summaries. Data collected from each article included publication details: authors, year, study design and follow-up duration; patient characteristics: JIA subtype, age, gender and disease duration; intervention: biologic agent, treatment duration, exposure, dosage, schedule, route of administration and concomitant therapy; outcomes: ADAb prevalence, therapeutic response, drug concentrations, adverse events and ADAb detection method.

The primary outcome was the prevalence of ADAbs. Secondary outcomes were the association of ADAbs with efficacy, the association of ADAbs with drug concentration, the association of ADAbs with adverse events and the effect of immunosuppressive therapy on the formation of ADAbs.

Quality assessment
------------------

The validity of ADAb detection of included studies was assessed based on individual components of the Cochrane risk of bias tool and the STROBE checklist \[[@kez030-B16], [@kez030-B17]\]. The following characteristics of included studies were taken into consideration to address (risk of) bias influencing development of ADAbs: eligibility criteria resulting in a study population with a specific drug response (selection bias), not accounting for variables (i.e. concomitant therapy) that could influence development of ADAbs (effect modification), incomplete reporting of ADAb detection method or timing of antibody measurements (detection method), incomplete outcome data (attrition bias) and selective reporting of outcomes (reporting bias).

Statistical analysis
--------------------

In order to provide a meaningful review, meta-analyses were only performed when studies were sufficiently homogeneous with regard to outcome criteria. Proportional and pairwise meta-analyses were performed using the 'meta' package (version 4.9--2) in 'R' version 3.5.1. (R Foundation for Statistical Computing, Vienna, Austria). Studies that restricted ADAb measurements to a specific subset of the study population were excluded from the meta-analysis of prevalence. Prevalence estimates of ADAbs were reported as percentages, stratified by biologic agent and variance was calculated using double arcsine transformation \[[@kez030-B18]\]. Where possible, secondary outcomes were analysed by meta-analysis of risk ratios. Assuming methodological and clinical heterogeneity across studies, all meta-analyses were performed using random effects methods. Variance was expressed as 95% confidence interval. Heterogeneity was examined by calculating *I^2^* for inconsistency (Der Simonian-Laird). Forest plots were generated and sorted by sample size to assess publication bias. Meta-analyses were stratified by important study variables including ADAb detection method, concomitant immunosuppressive therapy, age and follow-up duration to assess substantial (*I^2^*\> 40%) heterogeneity between studies.

Results
=======

The flow-chart of the selection of studies is presented in [Fig. 1](#kez030-F1){ref-type="fig"}. The database search generated 5183 records after duplicates were removed. After screening on title and abstract, 150 full-text articles reporting efficacy, safety, pharmacokinetics or immunogenicity of biologic agents in JIA patients remained. Primarily, 108 articles were excluded because ADAb measurements were not included. A total of 28 full-text articles, involving 26 studies, met eligibility criteria and were included in the qualitative analysis. In addition, 21 studies were included in the meta-analysis of prevalence and six studies were evaluated for the effect of immunosuppressive therapy on the formation of ADAbs.

![Flow-chart of the selection of studies\
ADAb: anti-drug antibody.](kez030f1){#kez030-F1}

Overall, 26 studies provided data of 2354 individual JIA patients receiving the following biologic agents: four TNF inhibitors (etanercept, *n* = 268 \[[@kez030-B19]\]; infliximab, *n* = 122 \[[@kez030-B23], [@kez030-B24]\]; adalimumab, *n* = 355 \[[@kez030-B25]\]; golimumab, *n* = 173 \[[@kez030-B32]\]), one anti-IL6 (tocilizumab, *n* = 716 \[[@kez030-B33]\]), one anti-CTLA4 (abatacept, *n* = 409 \[[@kez030-B39]\]) and three anti-IL1 (anakinra, *n* = 86 \[[@kez030-B42]\]; canakinumab, *n* = 201 \[[@kez030-B43]\]; rilonacept, *n* = 24 \[[@kez030-B46]\]). Longitudinal studies with multiple publications were available for treatment with etanercept (up to 96 weeks) \[[@kez030-B22]\], infliximab (up to 204 weeks) \[[@kez030-B24]\], tocilizumab (up to 168 weeks) \[[@kez030-B35]\], abatacept (up to 7 years) \[[@kez030-B40]\] and canakinumab (at least 104 weeks) \[[@kez030-B45]\]. Immunogenicity data and baseline patient characteristics of canakinumab studies were described in separate articles. Therefore, Sun *et al.* \[[@kez030-B45]\] was included in the meta-analysis of prevalence and Ruperto *et al.* \[[@kez030-B43], [@kez030-B44]\] were included for patient characteristics at baseline. Characteristics of all included studies and patients at baseline are provided in [Table 1](#kez030-T1){ref-type="table"}.

###### 

Characteristics of included studies and patients at baseline

  Study                                                                              JIA subtype            Drug       Dosage                                                                               Design              Primary outcome   Patients (*n*)   Female (%)   Follow- up, weeks                             Age, years[^a^](#tblfn1){ref-type="table-fn"}   Disease duration, years[^a^](#tblfn1){ref-type="table-fn"}   MTX (%)   Other DMARDs (%)   CS (%)   ADAb detection method
  ---------------------------------------------------------------------------------- ---------------------- ---------- ------------------------------------------------------------------------------------ ------------------- ----------------- ---------------- ------------ --------------------------------------------- ----------------------------------------------- ------------------------------------------------------------ --------- ------------------ -------- -----------------------
  Lovell *et al.* 2000 \[[@kez030-B19]\]                                             pcJIA                  ETN s.c.   0.4 mg/kg, 2xw                                                                       OL--RCT             Efficacy          69               62           28                                            10.5                                            5.9                                                          0         0                  36       NA
  Mori *et al.* 2012 \[[@kez030-B20]\]                                               pcJIA                  ETN s.c.   0.2 mg/kg, 0.4 mg/kg, 2xw                                                            LTE                 Efficacy          32               88           96                                            13.7                                            6.1                                                          0         0                  81       NA
  Alcobendas *et al.* 2016 \[[@kez030-B21]\]                                         oJIA, pJIA, ERA, PsA   ETN s.c.   0.8 mg/kg, qw                                                                        RO                  ADAbs             40               68           NA                                            11.3 (3.5)                                      NA                                                           20        NA                 NA       ELISA
  Constantin *et al.* 2016 \[[@kez030-B22]\]                                         oJIA, ERA, PsA         ETN s.c.   0.8 mg/kg, qw                                                                        OL                  Efficacy          127              57           96                                            11.7 (4.5)                                      2.23 (2.2)                                                   68        18                 13       NA
  Ruperto *et al.* 2007/2010 \[[@kez030-B23], [@kez030-B24]\]                        pcJIA                  IFX i.v.   6 mg/kg, q8w[^b^](#tblfn2){ref-type="table-fn"}                                      OL--RCT--LTE        Efficacy          62               79           204                                           11.1 (4.0)                                      3.6 (3.4)                                                    100       0                  34       ELISA
  3mg/kg, q8w[^c^](#tblfn3){ref-type="table-fn"}                                     60                     88         204                                                                                  11.3 (4.0)          4.2 (3.6)         100              0            43                                                                                                                                                                                               
  Lovell *et al.* 2008 \[[@kez030-B25]\]                                             pcJIA                  ADA s.c.   24 mg/m^2^, q2w                                                                      OL--RCT             Efficacy          85               80           48                                            11.4 (3.3)                                      4.0 (3.7)                                                    100       0                  5        NA
  86                                                                                 78                     48         11.1 (3.8)                                                                           3.6 (4.0)           0                 0                2                                                                                                                                                                                                             
  Imagawa *et al.* 2012 \[[@kez030-B26]\]                                            pcJIA                  ADA s.c.   20 mg (\<30 kg), 40 mg (≥30 kg), q2w                                                 OL                  Efficacy          25               80           60                                            13.0 (3.38)                                     4.7 (3.72)                                                   80        0                  72       ELISA
  Kingsbury *et al.* 2014 \[[@kez030-B27]\]                                          pcJIA                  ADA s.c.   24 mg/m^2^, q2w                                                                      OL                  Safety            32               88           24                                            3.0 (0.72)                                      1.0 (0.78)                                                   84        3                  63       ELISA
  Burgos-Vargas *et al.* 2015 \[[@kez030-B28]\]                                      ERA                    ADA s.c.   24 mg/m^2^, q2w                                                                      RCT--LTE            Efficacy          46               33           52                                            12.9 (2.9)                                      2.6 (2.3)                                                    52        20                 NA       NA
  Skrabl-Baumgartner *et al.* 2015 \[[@kez030-B29]\]                                 oJIA, pJIA, ERA        ADA s.c.   24 mg/m^2^, q2w                                                                      PO                  Efficacy          23               87           208                                           14.2 (7.9--17.2)                                NA                                                           74        NA                 NA       ELISA
  Leinonen *et al.* 2017 \[[@kez030-B30]\]                                           JIA-uveitis            ADA s.c.   24 mg/m^2^, q2w                                                                      RO                  ADAbs             9                NA           104                                           9.3 \[3.7--14.9\]                               NA                                                           29        NA                 NA       NA
  22                                                                                 NA                     104        9.8 \[4.4--16.8\]                                                                    NA                  91                NA               NA                                                                                                                                                                                                            
  Marino *et al.* 2018 \[[@kez030-B31]\]                                             oJIA, pJIA, ERA        ADA s.c.   24 mg/m^2^, q2w                                                                      PO                  ADAbs             27               NA           64                                            9.5 (3.3)                                       4.79 (3.0)                                                   59        0                  0        SPR
  Brunner *et al.* 2018 \[[@kez030-B32]\]                                            pcJIA                  GLM s.c.   30 mg/m^2^, q4w                                                                      OL--RCT             Efficacy          173              76           48                                            11.2 (4.4)                                      NA                                                           100       0                  24       ELISA
  De Benedetti *et al.* 2012 \[[@kez030-B33]\]                                       sJIA                   TCZ i.v.   8 mg/kg (\<30 kg), 12 mg/kg (≥30 kg), q2w                                            RCT--LTE            Efficacy          37 PCB           46           52                                            9.1 (4.4)                                       5.1 (4.4)                                                    70        0                  84       NA
  75 TCZ                                                                             52                     52         10.0 (4.6)                                                                           5.2 (4.0)           69                0                93                                                                                                                                                                                                            
  Imagawa *et al.* 2012 \[[@kez030-B34]\]                                            pcJIA                  TCZ i.v.   8mg/kg, q4w                                                                          OL                  Efficacy          19               79           48                                            12 \[3--9\]                                     4.7 \[1--17\]                                                0         0                  NA       NA
  Yokota *et al.* 2014 \[[@kez030-B35]\]                                             sJIA                   TCZ i.v.   8 mg/kg, q2w                                                                         OL--RCT--LTE        Safety            67               57           168                                           8.3 (4.3)                                       4.4 (3.5)                                                    0         0                  100      ELISA
  Brunner *et al.* 2015 \[[@kez030-B36]\]                                            pcJIA                  TCZ i.v.   8 mg/kg (≥30 kg),8--10 mg/kg (\<30 kg), q4w                                          OL--RCT             Efficacy          188              77           40                                            11.0 (4.01)                                     4.2 (3.67)                                                   79        0                  46       NA
  Yokota *et al.* 2016 \[[@kez030-B37]\]                                             sJIA                   TCZ i.v.   8 mg/kg, q2w                                                                         OL                  Safety            417              48           52                                            11.2 (7.2)                                      5.8 (5.9)                                                    26        18                 88       NA
  Yasuoka *et al.* 2018 \[[@kez030-B38]\]                                            sJIA                   TCZ i.v.   8 mg/kg, q2w                                                                         RO                  Safety            35 ISR−          60           12                                            7.4 \[2.8--25.9\]                               1.3 \[0--14.4\]                                              NA        NA                 100      ELISA
  5 ISR+                                                                             100                    12         2.5 \[2.1--10.5\]                                                                    0.17 \[0.1--1.8\]   NA                NA               100                                                                                                                                                                                                           
  Ruperto *et al.* 2010 \[[@kez030-B39]\] / Lovell *et al.* 2015 \[[@kez030-B40]\]   pcJIA                  ABA i.v.   10 mg/kg, q4w                                                                        LTE                 Efficacy          190              72           270 (91)[^d^](#tblfn4){ref-type="table-fn"}   12.4 (3.0)                                      4.4 (3.8)                                                    74        0                  28       ELISA
  Brunner *et al.* 2018 \[[@kez030-B41]\]                                            pcJIA                  ABA s.c.   50 mg (\<25 kg),87.5 mg (\<50 kg),125 mg (≥50 kg), qw                                OL                  PK                173              79           104                                           13.0 (10.0--15.0)                               2.0 (0.0--4.0)                                               79        NA                 32       NA
  46                                                                                 61                     104        4.0 (3.0--5.0)                                                                       0.5 (0.0--1.0)      80                NA               20                                                                                                                                                                                                            
  Ilowite *et al.* 2009 \[[@kez030-B42]\]                                            pcJIA                  ANA s.c.   1 mg/kg, qd                                                                          OL--RCT--LTE        Safety            86               73           80                                            12 (3--17)[^e^](#tblfn5){ref-type="table-fn"}   4.7 (1--16)[^e^](#tblfn5){ref-type="table-fn"}               78        29                 58       SPR
  Ruperto *et al.* 2012 \[[@kez030-B43]\]                                            sJIA                   CNK s.c.   Stage 1 (15 days): 0.5 mg/kg, 1.5 mg/kg, 4.5 mg/kg, SD or DD.Stage 2: 4 mg/kg, q4w   OL--LTE             Efficacy          23               48           104                                           10 \[4--19\]                                    3.2 \[0.6--17\]                                              26        0                  83       SPR
  Ruperto *et al.* 2012 \[[@kez030-B44]\]                                            sJIA                   CNK s.c.   4 mg/kg, SD                                                                          RCT                 Efficacy          41 PCB           56           4                                             9.0 (6.0--14.0)                                 2.0 (1.2--5.2)                                               59        0                  68       ECL
  43 CNK                                                                             63                     4          8.0 (4.0--13.0)                                                                      2.3 (1.0--4.7)      67                0                72                                                                                                                                                                                                            
  Ruperto *et al.* 2012 \[[@kez030-B44]\]                                            sJIA                   CNK s.c.   4 mg/kg, q4w                                                                         OL--RCT--LTE        Efficacy          177 CNK          55           104                                           8.0 (5.0--12.0)                                 2.1 (0.8--4.3)                                               53        0                  72       
  Lovell *et al.* 2013 \[[@kez030-B46]\]                                             sJIA                   RLN s.c.   2.2 mg/kg, 4.4 mg/kg, qw[^f^](#tblfn6){ref-type="table-fn"}                          RCT--LTE            Safety            24               67           104                                           12.6 (4.3)                                      3.1                                                          NA        0                  NA       NA

Age and disease duration are presented as mean, mean ([s]{.smallcaps}.[d]{.smallcaps}.), median (interquartile range), or median \[range\].

Placebo at week 0, 2 and 6; induction with 6 mg/kg at 14, 16 and 20 weeks.

Induction with 3 mg/kg at 0, 2, 6, 14 weeks, placebo at 16 weeks and 3 mg/kg at 20 weeks.

Data are presented as mean ([s]{.smallcaps}.[d]{.smallcaps}.).

Data are presented as mean (range).

Induction with same dose of rilonacept on day 0, 3, 7, 14 and 21. ABA: abatacept; ADA: adalimumab; ADAb: anti-drug antibody; ANA: anakinra; CNK: canakinumab; DD: double dose; ECL: electrochemiluminescence; ERA: enthesitis-related arthritis; ETN: etanercept; GLM: golimumab; IFX: infliximab; ISR: infusion site reaction; LTE: long-term extension study; NA: not available; OD: on demand dose-escalation; OL: open-label study; (e)oJIA: (extended) oligoarticular JIA; PCB: placebo; pcJIA: polyarticular-course JIA (defined as ≥5 inflamed joints at enrolment or in patient history, without systemic symptoms); pJIA: polyarticular JIA; PK: pharmacokinetics; PO: prospective observational study; PsA: psoriatic arthritis; qd: every day; qw: every week; qxw: every *x* weeks; RCT: randomized clinical trial; RLN: rilonacept; RO: retrospective observational study; SD: single dose; SPR: surface plasmon resonance; sJIA: systemic JIA; TCZ: tocilizumab; 2xw: twice weekly.

Risk of bias within individual studies was assessed using predefined criteria. ADAb detection methods or timing of immunogenicity assessments were not available for 12 out of 26 studies \[[@kez030-B19], [@kez030-B20], [@kez030-B22], [@kez030-B25], [@kez030-B28], [@kez030-B30], [@kez030-B33], [@kez030-B34], [@kez030-B36], [@kez030-B37], [@kez030-B41], [@kez030-B46]\]. Studies that did report timing of immunogenicity assessments, measured ADAbs at baseline, at the end of an open-label phase, at the end of a placebo-controlled phase and at several visits during an open-label extension phase (simultaneously with visits for efficacy and safety assessments). In nine studies, an ELISA was used to detect ADAbs \[[@kez030-B21], [@kez030-B26], [@kez030-B27], [@kez030-B29], [@kez030-B32], [@kez030-B35], [@kez030-B38]\]. Three studies used surface plasmon resonance-based assays \[[@kez030-B31], [@kez030-B42], [@kez030-B43]\] and two studies used electrochemiluminescence to detect ADAbs \[[@kez030-B44]\]. Few studies were completely without risk of bias influencing ADAb detection. A full summary of the risk of bias assessment is provided in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online.

Prevalence of ADAbs in JIA
--------------------------

The prevalence of ADAbs varied considerably from 0% to 82% with an overall pooled prevalence of 16.9% (95% CI 9.5, 25.9) ([Fig. 2](#kez030-F2){ref-type="fig"}). Proportional meta-analysis of ADAb prevalence demonstrated high heterogeneity between studies (*I^2^* = 95%) ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). After studies were grouped by biologic agent, remaining heterogeneity between studies was substantially reduced through subgroup analyses of important study variables including ADAb detection method, the use of concomitant MTX and follow-up duration (Supplementary Figs S2--S5, available at *Rheumatology* online). Forest plots showed no evidence of publication bias.

![Random effects meta-analysis of ADAb prevalence in JIA stratified by biologic agent\
ADAbs: anti-drug antibodies; AEs: adverse events; NA: not available; TF: treatment failure; +: strong association with ADAbs; +/−: possible association with ADAbs; −: no association with ADAbs.](kez030f2){#kez030-F2}

Four studies reported additional point prevalence of ADAbs at different time points \[[@kez030-B22], [@kez030-B26], [@kez030-B42]\]. Treatment of 127 patients with etanercept resulted in ADAb development in 5% at 12 weeks, 12% at 48 weeks, 13% at 96 weeks and in 21% of patients overall, while only 38% (10/26) with ADAbs tested positive more than once \[[@kez030-B22]\]. In infliximab-treated patients, ADAbs were detected in 25% at 52 weeks, increasing to 37% at 204 weeks \[[@kez030-B23], [@kez030-B24]\]. For adalimumab, ADAbs were detected in 8% at 8 weeks, increasing to 24% having at least one and 8% having at least two ADAb-positive samples at 60 weeks \[[@kez030-B26]\]. Marino *et al.* \[[@kez030-B31]\] reported that 30% of patients with ADAbs tested positive more than once. Prevalence of antibodies to anakinra increased from 75% at 12 weeks to 82% at 12 months \[[@kez030-B42]\]. Although antibodies to tocilizumab were also detected within 12 weeks, prevalence of ADAbs did not appear to increase with longer treatment duration \[[@kez030-B33]\]. During treatment with intravenous and subcutaneous abatacept, the majority of ADAb-positive patients tested positive only once (59% and 50%, respectively) \[[@kez030-B39]\]. Studies of golimumab and rilonacept did not report ADAb testing at different time points \[[@kez030-B32], [@kez030-B46]\]. For canakinumab, only one patient demonstrated persistent immunogenicity (⩾2 ADAb-positive samples), which resolved after continued treatment \[[@kez030-B45]\].

Treatment failure and ADAbs
---------------------------

Although treatment with etanercept induced ADAbs in some patients, detected ADAbs were non-neutralizing and none of the etanercept studies reported an association between treatment failure and the presence of non-neutralizing ADAbs ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online) \[[@kez030-B19]\]. Similarly, studies of abatacept and rilonacept also did not report an association between the presence of ADAbs and treatment failure \[[@kez030-B39], [@kez030-B40], [@kez030-B46]\]. In contrast, clinical response to infliximab was less frequently achieved by patients with ADAbs compared with patients without ADAbs (67% *vs* 79%, respectively). Moreover, patients treated with 6 mg/kg infliximab achieved better maintenance of drug concentrations and exhibited lower rates of ADAbs compared with patients treated with 3 mg/kg (12% *vs* 38%, respectively) \[[@kez030-B23]\]. In adalimumab studies, increasing median disease activity scores and significantly lower adalimumab concentrations were observed in patients with ADAbs (1.63 mg/l *vs* 14.13 mg/l) \[[@kez030-B29], [@kez030-B31]\]. Likewise, in patients with JIA-associated uveitis, antibodies to adalimumab were associated with a significant higher grade of uveitis and lower median trough concentration (\<0.01 mg/l *vs* 9.4 mg/l) \[[@kez030-B30]\]. Nevertheless, two adalimumab studies did not observe an association between the presence of ADAbs and treatment failure but these analyses were not published \[[@kez030-B25], [@kez030-B28]\]. Neutralizing potential of antibodies to infliximab or adalimumab was not determined. In patients treated with golimumab, neutralizing ADAbs were detected in 46% (30/66) of ADAb-positive patients. Although high titres (\>1: 1000) neutralizing antibodies to golimumab were associated with lower trough concentrations, seven out of eight patients with high antibody titres achieved clinical response to golimumab \[[@kez030-B32]\]. Three studies of tocilizumab reported on ADAbs and treatment efficacy. Despite low immunogenicity of tocilizumab overall, 43% (3/7) of patients with neutralizing ADAbs discontinued treatment due to primary or secondary failure compared with 6% (17/267) of ADAb-negative patients \[[@kez030-B34]\]. Antibodies to anakinra were also associated with lack of efficacy in all (4/64) patients who tested positive for neutralizing antibodies at 12 weeks \[[@kez030-B42]\]. However, none of the remaining patients tested positive for neutralizing ADAbs during 12 months of extended treatment with anakinra and non-neutralizing antibodies to anakinra were not associated with treatment failure \[[@kez030-B42]\]. All antibodies to canakinumab lacked neutralizing potential and none of the ADAb-positive patients experienced treatment failure or exhibited decreased drug concentrations \[[@kez030-B45]\].

Adverse events and ADAbs
------------------------

During infliximab treatment, infusion reactions were observed in 58% (15/26) of infliximab-treated patients with ADAbs compared with 19% (5/26) in those without ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). Among those with ADAbs, infusion reactions occurred in 60% (12/20) of patients treated with 3 mg/kg infliximab *vs* 50% (3/6) of patients treated with 6 mg/kg infliximab. Moreover, 20% (4/20) of patients with ADAbs experienced a possible anaphylactic reaction *vs* none without ADAbs \[[@kez030-B23]\]. Overall, tocilizumab studies detected ADAbs in 68% (15/22) of patients with infusion reactions \[[@kez030-B33], [@kez030-B35], [@kez030-B37], [@kez030-B38]\]. Furthermore, all patients (9/23) who experienced ⩾3 injection site reactions to rilonacept also tested positive for ADAbs \[[@kez030-B46]\]. None of the ADAb-positive patients experienced injection site reactions in studies of canakinumab and subcutaneous abatacept \[[@kez030-B41], [@kez030-B45]\]. Although limited data were available, studies of etanercept, adalimumab, golimumab and intravenous abatacept did not report an association between the presence of ADAbs and adverse events \[[@kez030-B22], [@kez030-B25], [@kez030-B26], [@kez030-B32], [@kez030-B39], [@kez030-B40]\]. The association between antibodies to anakinra and adverse events was not analysed \[[@kez030-B42]\].

Concomitant immunosuppressive therapy
-------------------------------------

Six studies reported ADAb prevalence and stratified patients according to concomitant MTX therapy during treatment with adalimumab. The addition of MTX therapy reduced the risk of ADAb development with 67% in these studies (risk ratio 0.33; 95% CI 0.21, 0.52) \[[@kez030-B25], [@kez030-B26], [@kez030-B28]\] ([Fig. 3](#kez030-F3){ref-type="fig"}).

![Random effects meta-analysis of concomitant MTX and the risk of ADAb development during adalimumab treatment\
ADAbs: anti-drug antibodies; RR: risk ratio.](kez030f3){#kez030-F3}

Patients who received concomitant MTX were also included in studies of other biologic agents (i.e. anakinra, rilonacept, etanercept, abatacept and tocilizumab). However, patients were not stratified according to immunosuppressive therapy and thus other pairwise meta-analyses were not performed \[[@kez030-B22], [@kez030-B37], [@kez030-B39], [@kez030-B46]\].

Discussion
==========

The percentage of patients with JIA that developed ADAbs varied widely across nine different biologics (0--82%) with a pooled prevalence of 16.9% (95% CI 9.5, 25.9). Although prevalence of ADAbs within studies generally increased with longer treatment duration, ADAbs appeared transient in most patients \[[@kez030-B22], [@kez030-B31], [@kez030-B39]\]. Nevertheless, the presence of antibodies against biologic agents was associated with primary failure, secondary failure or hypersensitivity-associated events, which was most evident in studies of infliximab and adalimumab \[[@kez030-B23], [@kez030-B24], [@kez030-B29], [@kez030-B31]\]. Although detected in a small number of patients, neutralizing antibodies to tocilizumab or anakinra were also associated with primary or secondary failure. Furthermore, a much higher prevalence of antibodies to tocilizumab was observed in patients with hypersensitivity-associated events. These results indicate the clinical relevance of ADAbs in JIA patients treated with these biologic agents. In contrast, antibodies to etanercept, abatacept or canakinumab did not appear to be associated with treatment failure or adverse events.

Heterogeneity was high in the meta-analysis of ADAb prevalence and pooled results over all studies should be interpreted with caution. However, stratification of meta-analysis by biologic agent and subgroup analyses by ADAb detection method, concomitant immunosuppressive therapy and follow-up duration significantly reduced the amount of unexplained variability. However, immunogenicity of biologic therapies is affected by many more factors, both intrinsic (e.g. foreign or T cell epitopes, aggregation, post-translational modifications and target molecules) and extrinsic (e.g. route of administration, concomitant immunosuppressive therapy and underlying pathology) \[[@kez030-B47]\]. Therefore, we acknowledge that the observed heterogeneity of ADAb prevalence between studies could also be explained by other variables.

Receptor constructs, such as etanercept and abatacept, might offer an advantage over humanized and fully human antibodies regarding clinical impact of ADAbs on efficacy and safety. This might be explained by the fact that only the linker region of receptor constructs contains foreign epitopes and receptor constructs do not express an idiotope (i.e. antigen-binding region), resulting in a lack of neutralizing antibodies \[[@kez030-B12]\]. Furthermore, low immunogenicity of some biologics might also be associated with inhibition of their target molecule. For example, tocilizumab and canakinumab inhibit IL-6 and IL-1β respectively, which are both essential for T cell-dependent antibody production \[[@kez030-B48], [@kez030-B49]\].

The detection of ADAbs is technically challenging and the large variation between assays influences results of immunogenicity assessments. Three studies used surface plasmon resonance-based assays, which allows for a more accurate detection of low-affinity ADAbs than ELISA or electrochemiluminescence. Antibodies to adalimumab were indeed more frequently detected by Marino *et al.* using a surface plasmon resonance-based assay compared with studies of adalimumab using ELISAs (37% *vs* 7--26%) \[[@kez030-B26], [@kez030-B27], [@kez030-B29], [@kez030-B31], [@kez030-B50]\]. Therefore, standardization of assay methods is necessary to provide consequent immunogenicity assessments across studies and biologic agents.

Nonetheless, the association of ADAbs with treatment failure and adverse events indicates the importance of strategies to manage immunogenicity in paediatric patients with JIA. Lower drug concentrations were associated with the presence of ADAbs and thus maintenance of therapeutic drug concentrations appears to be of importance. This is in agreement with the 'discontinuity theory' of the immune system, in which the intermittent appearance of an antigen promotes a long-lasting immune response \[[@kez030-B51]\]. In addition to maintenance of drug concentrations, concomitant therapy with MTX significantly reduced the risk of ADAbs in paediatric patients, as well as in adults, indicating that both strategies are valuable to prevent the development of ADAbs \[[@kez030-B9], [@kez030-B10], [@kez030-B52]\].

Considering technical challenges and the association of drug concentrations with the presence of ADAbs, regular measurements of drug trough concentrations may be preferred over immunogenicity assessments in clinical practice. Furthermore, antibodies to biologic agents frequently affect clinical efficacy and safety in a small number of patients. Therefore, we recommend a preliminary course of action using trough concentration measurements in patients who experience primary failure, secondary failure or hypersensitivity-associated events, based on previously reported algorithms for patients with RA \[[@kez030-B53]\] ([Fig. 4](#kez030-F4){ref-type="fig"}).

![Course of action for treatment failure or hypersensitivity during JIA treatment with biologic agents\
Treatment failure (primary or secondary) or hypersensitivity-associated events: assess serum drug trough concentration. (i) Sufficient drug concentration: switch to a biologic agent of a different class. (ii) Insufficient drug concentration: measure ADAbs. (a) ADAb-negative: (1) assess and (re-)adjust dosage to patient's weight; (2) assess and optimize therapeutic compliance; (3) optimal compliance and maximum dosage: switch to a biologic agent of a different class. (b) ADAb-positive: neutralize ADAbs: (1) immunosuppressive therapy, (2) dose escalation, (3) switch to another biologic agent -- identical or different class. ADAb: anti-drug antibody; ?: research question for future research.](kez030f4){#kez030-F4}

Current guidelines recommend switching to another biologic agent in case of treatment failure or discontinuation due to adverse events. However, studies of drug survival in patients with JIA have demonstrated reduced efficacy of second (and third) biologics, especially after switching due to primary failure \[[@kez030-B6], [@kez030-B8]\]. In case of treatment failure and the presence of ADAbs, strategies to counteract ADAbs could prevent switching to a second biologic with potentially reduced efficacy. ADAbs may disappear after dose escalation or continued treatment \[[@kez030-B26], [@kez030-B45]\]. However, De Benedetti *et al.* \[[@kez030-B33]\] reported severe adverse events after continued tocilizumab treatment in patients with ADAbs. More studies are warranted that address whether dose escalation is a safe strategy and which dose increase is required to counteract the presence of ADAbs. Moreover, the ability of immunosuppressive therapies to prevent antibody formation and to neutralize antibody formation after ADAbs have developed needs to be further investigated. Whether a biologic agent of the same class or a different class is more effective after discontinuation due to antibody formation is also not known.

There are some limitations to the interpretation of our results. A total of 12 studies did not include assay methods or timing of ADAb measurements, which could have influenced ADAb detection. Four studies found little correlation between ADAbs and reduced treatment efficacy or adverse events but did not report effect measures, indicating a high risk of selective outcome reporting in these studies and possible underestimation of the clinical impact of ADAbs \[[@kez030-B22], [@kez030-B32], [@kez030-B39], [@kez030-B40], [@kez030-B46]\]. Furthermore, outcomes were often not specifically reported for patients with or without ADAbs, which prevented pairwise meta-analyses of the association of ADAbs with treatment failure or adverse events.

Nevertheless, the prevalence of antibodies to infliximab, adalimumab, tocilizumab and canakinumab appeared similar in paediatric patients with JIA compared with adults with other chronic inflammatory diseases \[[@kez030-B53], [@kez030-B56], [@kez030-B57]\]. In contrast, antibodies to anakinra (0--3% *vs* 6%), rilonacept (35% *vs* 54%), golimumab (0--7% *vs* 47%), etanercept (0--18% *vs* 0--26%) and abatacept (1--3% *vs* 2--23%) were less frequently detected in adult patients with chronic inflammatory diseases \[[@kez030-B53], [@kez030-B55], [@kez030-B58], [@kez030-B59]\]. Brunner *et al.* \[[@kez030-B41]\] included two age groups (2--5 years *vs* 6--17 years) and detected a higher prevalence of antibodies to abatacept in the younger age group (2% *vs* 9%). Nonetheless, definite patient-related factors influencing immunogenicity have yet to be identified.

Conclusion
==========

This comprehensive systematic review and meta-analysis on immunogenicity of biologic therapies in JIA highlights that the presence of ADAbs is sometimes transient but can be associated with treatment failure and adverse events. Furthermore, standardization of immunogenicity assays is necessary to provide consistent results across studies and biologic agents. Immunogenicity of biologic therapies is of high clinical relevance and should be considered in case of treatment failure or hypersensitivity to biologic agents. Future research should focus on additional strategies to prevent the development of ADAbs and to maintain or restore clinical efficacy after ADAb development. Strategies to predict, prevent, detect and manage immunogenicity can potentially improve treatment outcomes and lead to a more personalized treatment with biologic therapies.
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